Abstract
Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as “synthetic lethality”. Nowadays, synthetic lethality has become a widely used anti-cancer strategy.
Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016. Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.Keywords: Synthetic lethality, targeted therapy, PARP inhibitors, drug resistance, cancer therapy, signaling pathways.
Graphical Abstract
Current Cancer Drug Targets
Title:Synthetic Lethal Interactions in Cancer Therapy
Volume: 17 Issue: 4
Author(s): Xinwei Geng, Xiaohui Wang, Dan Zhu*Songmin Ying*
Affiliation:
- Department of Respiratory Medicine, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, Jinhua,China
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou,China
Keywords: Synthetic lethality, targeted therapy, PARP inhibitors, drug resistance, cancer therapy, signaling pathways.
Abstract: Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as “synthetic lethality”. Nowadays, synthetic lethality has become a widely used anti-cancer strategy.
Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016. Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.Export Options
About this article
Cite this article as:
Geng Xinwei, Wang Xiaohui, Zhu Dan*, Ying Songmin*, Synthetic Lethal Interactions in Cancer Therapy, Current Cancer Drug Targets 2017; 17 (4) . https://dx.doi.org/10.2174/1568009616666160426122736
DOI https://dx.doi.org/10.2174/1568009616666160426122736 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry Synthetic Approaches to Various Class of Topoisomerase II Inhibitors
Mini-Reviews in Organic Chemistry Fluorescent GPCR Ligands as New Tools in Pharmacology-Update, Years 2008- Early 2014
Current Medicinal Chemistry Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology A Novel Monoclonal Antibody Against the C-terminus of β-Tubulin Recognizes Endocytic Organelles in Trypanosoma cruzi
Protein & Peptide Letters Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry A New Target for Diagnosis and Treatment of CNS Disorders: Agmatinergic System
Current Medicinal Chemistry Biosafety of Onco-Retroviral Vectors
Current Gene Therapy MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued)